logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

CSPC Pharma (01093) spent HK $29.8096 million to repurchase 6.44 million shares on September 17th.

date
16:54 17/09/2024
avatar
GMT Eight
Shiyao Group (01093) announced that the company spent HK$2980.96 million on September 17, 2024...
CSPC PHARMA (01093) announced that the company repurchased 6.44 million shares for a total of 29.8096 million Hong Kong dollars on September 17, 2024, with a buyback price of 4.58-4.66 Hong Kong dollars per share.
Related Articles
China Stock
GMTEight List of A-share restricted sales and lifting restrictions | May 5th
New Stock News | Jiangxi Biotechnology Submits Documents to the Hong Kong Stock Exchange for the Third Time
US Stock
Net profit surged nearly fourfold, and annual guidance was increased again! Palantir's (PLTR.US) US business had a "surge" in the first quarter, but commercial sales left regrets.
GMTEight List of A-share restricted sales and lifting restrictions | May 5th
China Stock
New Stock News | Jiangxi Biotechnology Submits Documents to the Hong Kong Stock Exchange for the Third Time
Net profit surged nearly fourfold, and annual guidance was increased again! Palantir's (PLTR.US) US business had a "surge" in the first quarter, but commercial sales left regrets.
US Stock
RECOMMEND
HKEX Signals Stronger Reforms While Upholding Listing Quality
HKEX Signals Stronger Reforms While Upholding Listing Quality
icon
02/05/2026
Retreat of Short Sellers Opens Valuation Window for Hong Kong’s AI Leaders
Retreat of Short Sellers Opens Valuation Window for Hong Kong’s AI Leaders
icon
02/05/2026
Explosive Token Growth Signals New Stage for China’s AI
Explosive Token Growth Signals New Stage for China’s AI
icon
02/05/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.